Kompass Onkologie最新文献_第8页

Psychosoziale Intervention: Über Bedarf, Akzeptanz und Machbarkeit in der pädiatrischen Onkologie 心理社会干预:儿科肿瘤学中需求，接受和可能性

Kompass Onkologie Pub Date : 2022-12-01 DOI: 10.1159/000528214

T. Zimmermann

{"title":"Psychosoziale Intervention: Über Bedarf, Akzeptanz und Machbarkeit in der pädiatrischen Onkologie","authors":"T. Zimmermann","doi":"10.1159/000528214","DOIUrl":"https://doi.org/10.1159/000528214","url":null,"abstract":"Objective Psychosocial screening is a standard of care in pediatric oncology, but there is limited information about how to intervene after screening. This pilot trial aimed to determine feasibility of the novel Enhanced Psychosocial Screening Intervention (EPSI) and explore its preliminary efficacy outcomes. We examined rates of recruitment, retention, intervention acceptability, and monthly distress screening completion, as well as exploratory efficacy outcomes (Patient-Reported Outcomes Measurement Information System: depression, anxiety and fatigue; distress thermometer, pain and sleep). Methods Parallel-group randomized pilot trial: Caregiver-youth (10–17 years at enrollment, newly diagnosed with cancer) dyads were randomly allocated to either EPSI or standard care with 1:1 ratio allocation. EPSI consists of having a Psychosocial Navigator who shares screening results conducted near diagnosis and monthly for one year with treating teams and families, and provides recommendations tailored to screening results. Results Enrollment rate was 54% (38 dyads); retention was 90% and acceptability 86% (caregivers) and 76% (youth). Exploratory symptoms of depression, anxiety, distress and fatigue outcomes consistently improved mainly for caregivers. Conclusions Results suggest EPSI is feasible and acceptable and exploratory mental and physical efficacy outcomes are promising for use in a future confirmatory multisite efficacy trial.","PeriodicalId":413988,"journal":{"name":"Kompass Onkologie","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129354084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Behandlung unfitter AML-Patient*innen: Paradigmenwechsel 疗法aml病患转换

Kompass Onkologie Pub Date : 2022-09-01 DOI: 10.1159/000526926

引用次数: 0

Mantelzelllymphom: Die Kombination verschiedener Therapien führt zum Erfolg 斗篷细胞淋巴瘤:许多疗法的配合

Kompass Onkologie Pub Date : 2022-09-01 DOI: 10.1159/000526780

M. Dreyling

引用次数: 0

Geriatrisches Ko-Management in der Hämatologie: Bloß nicht entmutigen lassen! 不要灰心丧气!

Kompass Onkologie Pub Date : 2022-09-01 DOI: 10.1159/000526395

N. Neuendorff

{"title":"Geriatrisches Ko-Management in der Hämatologie: Bloß nicht entmutigen lassen!","authors":"N. Neuendorff","doi":"10.1159/000526395","DOIUrl":"https://doi.org/10.1159/000526395","url":null,"abstract":"We conducted a randomized controlled trial in older adults with hematologic malignancies to determine the impact of geriatrician consultation embedded in our oncology clinic alongside standard care. From February 2015 to May 2018, transplant-ineligible patients aged ≥75 years who presented for initial consultation for lymphoma, leukemia, or multiple myeloma at Dana-Farber Cancer Institute (Boston, MA, USA) were eligible. Pre-frail and frail patients, classified based on phenotypic and deficit-accumulation approaches, were randomized to receive either standard oncologic care with or without consultation with a geriatrician. The primary outcome was 1-year overall survival. Secondary outcomes included unplanned care utilization within 6 months of follow-up and documented end-of-life (EOL) goals-of-care discussions. Clinicians were surveyed as to their impressions of geriatric consultation. One hundred sixty patients were randomized to either geriatric consultation plus standard care (n = 60) or standard care alone (n = 100). The median age of the patients was 80.4 years (standard deviation = 4.2). Of those randomized to geriatric consultation, 48 (80%) completed at least one visit with a geriatrician. Consultation did not improve survival at 1 year compared to standard care (difference: 2.9%, 95% confidence interval: –9.5% to 15.2%, P = 0.65), and did not significantly reduce the incidence of emergency department visits, hospital admissions, or days in hospital. Consultation did improve the odds of having EOL goals-of-care discussions (odds ratio = 3.12, 95% confidence interval: 1.03 to 9.41) and was valued by surveyed hematologic-oncology clinicians, with 62.9%–88.2% of them rating consultation as useful in the management of several geriatric domains.","PeriodicalId":413988,"journal":{"name":"Kompass Onkologie","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127703712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mantelzelllymphom: Die wirkungsvollste ist nicht immer die beste Therapie 曼德拉细胞淋巴管:最管用的不是最佳的治疗方法

Kompass Onkologie Pub Date : 2022-09-01 DOI: 10.1159/000526801

R. Claus, S. Sommer

{"title":"Mantelzelllymphom: Die wirkungsvollste ist nicht immer die beste Therapie","authors":"R. Claus, S. Sommer","doi":"10.1159/000526801","DOIUrl":"https://doi.org/10.1159/000526801","url":null,"abstract":"Ibrutinib, ein Bruton-Tyrosinkinase-Inhibitor, kann bei älteren Patienten mit unbehandeltem Mantelzelllymphom einen klinischen Nutzen haben, wenn er in Kombination mit Bendamustin und Rituximab verabreicht wird, gefolgt von einer Rituximab-Erhaltungstherapie. Im Rahmen der SHINE Studie haben Patienten ab 65 Jahren nach dem Zufallsprinzip entweder Ibrutinib oder Placebo sowie 6 Zyklen von Bendamustin und Rituximab erhalten. Sprachen die Patienten auf die Therapie an (vollständiges oder teilweises Ansprechen), erhielten sie eine Erhaltungstherapie mit Rituximab, die alle 8 Wochen verabreicht wurde. Der primäre Endpunkt war das progressionsfreie Überleben. Auch das Gesamtüberleben und die Sicherheit wurden bewertet. Von den 523 Patienten wurden 261 nach dem Zufallsprinzip für die Behandlung mit Ibrutinib und 262 für die Behandlung mit Placebo ausgewählt. Bei einer medianen Nachbeobachtungszeit von 84,7 Monaten betrug die mediane progressionsfreie Überlebenszeit 80,6 Monate in der Ibrutinib-Gruppe und 52,9 Monate in der Placebo-Gruppe (Hazard Ratio für Krankheitsprogression oder Tod, 0,75; 95% Konfidenzintervall, 0,59 bis 0,96; P = 0,01). Der Prozentsatz der Patienten mit einem vollständigen Ansprechen betrug 65,5% in der Ibrutinib-Gruppe und 57,6% in der Placebo-Gruppe (P = 0,06). Das Gesamtüberleben war in beiden Gruppen ähnlich. Die Inzidenz von unerwünschten Ereignissen des Grades 3 oder 4 während der Behandlung betrug 81,5 % in der Ibrutinib-Gruppe und 77,3 % in der Placebo-Gruppe.","PeriodicalId":413988,"journal":{"name":"Kompass Onkologie","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130013846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mantelzelllymphom: Chemotherapiefreie Kombination im Rezidiv richtig dosieren 纽扣细胞巴哈:下列非细胞浸液

Kompass Onkologie Pub Date : 2022-09-01 DOI: 10.1159/000526837

R. Marks

{"title":"Mantelzelllymphom: Chemotherapiefreie Kombination im Rezidiv richtig dosieren","authors":"R. Marks","doi":"10.1159/000526837","DOIUrl":"https://doi.org/10.1159/000526837","url":null,"abstract":"Relapsed Mantle cell lymphoma (MCL) is often treated with Bruton's tyrosine kinase inhibitors (BTKi); however, post-BTKi relapse can be challenging. Adding venetoclax (VEN) to ibrutinib (IBR) has shown synergy in preclinical MCL models. Prior MCL studies of the combination show promising efficacy but have conducted limited dose finding. We sought to identify the optimal dosing combination, based on efficacy and toxicity, utilizing a continual reassessment method of 6 combinations of IBR (280 mg, 420 mg, and 560 mg by mouth daily) and VEN (max dose of 200 mg and 400 mg by mouth daily). Eligible participants were not previously exposed to BTKi and not high risk for tumor lysis syndrome (TLS). VEN, initiated first at 100 mg, then at 20 mg by mouth daily after a TLS event, was started prior to adding IBR and ramped-up based on the dose level assigned. Combination treatment continued for six 28-day cycles. Thirty-five participants were enrolled and treated. One TLS event occurred with starting dose of 100 mg VEN; no TLS was seen with 20 mg. The optimal dosing combination was considered to be VEN 200 mg and IBR 420 mg with an overall response rate (ORR) of 93.8% (95% CI: 73.6% to 99.7%) and DLT incidence of 6.2% (95% CI: 0.3% to 26.4%). ORR for all arms was 82.3% (28/34; 95% CI: 65.5% to 93.2%) with a complete response (CR) rate of 42.4% (14/33; 95% CI: 25.5% to 60.8%). A participant was not allocated to IBR 560 mg and VEN 400 mg. ORR benefit was not seen with higher dosing combinations and toxicity was higher; a comparison made within the limitations of small cohorts. Resistance was seen in nearly all arms. This trial was registered at www.clinicaltrials.gov #NCT02419560.","PeriodicalId":413988,"journal":{"name":"Kompass Onkologie","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134192746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ibrutinib Plus R-ICE induziert Remission bei blastoider Variante eines Mantelzelllymphoms mit ZNS-Rückfall 伊布鲁蒂安双胞胎与r ice超导双胞胎南细胞淋巴瘤，zns复发

Kompass Onkologie Pub Date : 2022-09-01 DOI: 10.1159/000526309

Timothy S. Oh, Madelyn Burkart, Amir Behdad, Hatice Savas, Reem Karmali

{"title":"Ibrutinib Plus R-ICE induziert Remission bei blastoider Variante eines Mantelzelllymphoms mit ZNS-Rückfall","authors":"Timothy S. Oh, Madelyn Burkart, Amir Behdad, Hatice Savas, Reem Karmali","doi":"10.1159/000526309","DOIUrl":"https://doi.org/10.1159/000526309","url":null,"abstract":"Das Mantelzelllymphom (MCL) ist eine aggressive, schwer zu behandelnde Unterform des Lymphoms, die zu Rückfällen und schlechten Behandlungsergebnissen führt. Neuartige Wirkstoffe wie Bruton-Tyrosinkinase (BTK)-Inhibitoren wurden für die Behandlung von rezidiviertem/refraktärem (R/R) MCL untersucht. Insbesondere der BTK-Inhibitor Ibrutinib hat nachweislich die Überlebenschancen von R/R MCL-Patient*innen verbessert. Trotz dieser Fortschritte kommt es bei vielen MCL-Fällen, einschließlich der aggressiveren blastoiden und pleomorphen Varianten, zu einem Fortschreiten der Krankheit und damit zu schlechten Überlebensaussichten. Die blastoide Variante des MCL ist mit einem erhöhten Risiko einer Beteiligung des zentralen Nervensystems (ZNS) verbunden, was zu einer hohen Sterblichkeitsrate führt. In diesem Case Report berichten wir über einen Patienten mit der Diagnose eines blastoiden MCL mit ZNS-Rezidiv, der nach einer Standard Rituximab plus Ifosfamid-Carboplatin-Etoposid (R-ICE) Salvage-Chemotherapie mit dem Zusatz von Ibrutinib ein komplettes Ansprechen (CR) erreichte. Der Patient unterzog sich daraufhin einer autologen Stammzelltransplantation (autoSCT) und die CR konnte mit Ibrutinib aufrechterhalten werden.","PeriodicalId":413988,"journal":{"name":"Kompass Onkologie","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122128771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

OnkoCampus

Kompass Onkologie Pub Date : 2022-09-01 DOI: 10.1159/000526766

引用次数: 0

7 Fragen an PD Dr. Florian Scherer, ausgezeichnet mit dem Artur-Pappenheim-Preis 2021 " 12a " 2021年向警方询问Florian schner医生的7个问题

Kompass Onkologie Pub Date : 2022-09-01 DOI: 10.1159/000526272

引用次数: 0

Front & Back Matter 正面和背面

Kompass Onkologie Pub Date : 2022-09-01 DOI: 10.1159/000527055

引用次数: 0